Le Lézard
Classified in: Health, Business
Subject: LIC

ThriveAP and UPMC Enterprises Forge Groundbreaking Partnership with Growth Equity Infusion


UPMC Enterprises partners with ThriveAP to continue developing innovative solutions for the APP workforce.

NASHVILLE, Tenn., Feb. 21, 2024 /PRNewswire-PRWeb/ -- ThriveAP, the industry-leading educational organization dedicated to advancing support and education for the advanced practice provider (APP) workforce and their employers, announces a transformative partnership with UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC (University of Pittsburgh Medical Center). This strategic collaboration includes a significant growth equity infusion, marking a pivotal moment in ThriveAP's commitment to reshaping the landscape of healthcare education.

"This infusion propels ThriveAP's growth forward, enabling strategic investments in team expansion, innovative tech, and reinforcing clinician-led educational programs for improved patient outcomes and enterprise-wide benefits." - Jim Creason, CEO

ThriveAP enhances the transition-to-practice journey for both medical professionals and institutions. Through innovative programs and proven methodologies^, ThriveAP equips clinicians and employers with essential tools, knowledge and support crucial for successful careers. This pioneering approach surpasses traditional onboarding and ongoing education by offering comprehensive support systems and robust programs meticulously designed to bolster advanced practitioners' confidence and improve clinical performance. The result is superior patient outcomes^ and a competitive edge for healthcare employers.

Strategic Alliance Forged

The partnership between ThriveAP and UPMC Enterprises represents a unified vision for advancing healthcare education, characterized by a mutual dedication to crafting solutions that cater to the dynamic needs of clinicians, healthcare systems, and entities in both commercial and government sectors.

The growth equity infusion will be strategically channeled as working capital to drive pivotal corporate endeavors. These funds will bolster ThriveAP's programs, teams, and services, supporting the ongoing enhancement of its entire portfolio of APP workforce solutions. This encompasses initiatives such as skill assessment and development, facilitating seamless transitions into practice for broader clinical groups, certification preparation, and innovative solutions to meeting annual CE/CME requirements.

Jim Creason, President, and CEO of ThriveAP, expressed his enthusiasm for the partnership, highlighting the collaborative efforts with the UPMC team.

"Working alongside the incredibly talented team at UPMC Enterprises, we've been able to strategize both immediate and long-term impacts that this substantial infusion will produce. This exciting investment supports our acceleration toward continued growth through expansion of our teams, and additional resource allocation to new and innovative solutions to support the APP workforce."

The alliance between ThriveAP and UPMC Enterprises underscores the mutual commitment to developing solutions that cater to the evolving needs of clinicians, hospital systems, and medical institutions nationwide.

"The partnership between ThriveAP and UPMC Enterprises drives a better early career experience for APPs transitioning from an academic curriculum to patient care," said Ben Reynolds, Chief Advanced Practice Officer at UPMC. "Advanced practice is a growing field at UPMC and nationally. ThriveAP ensures APPs are practicing at the top of their license straight out of school, providing the highest quality and best care possible to our patients. "

^Banavich, 2019.

About ThriveAP

ThriveAP is an industry-leading educational institution recognized for transforming the transition-to-practice for medical professionals and institutions. Our focus is on enhancing the quality of care, improving patient access to care, positively influencing patient outcomes, and fostering provider fulfillment. ThriveAP's innovative programs and proven methodologies equip clinicians and healthcare employers with the essential tools, knowledge, and support necessary for a successful and fulfilling career.

About UPMC Enterprises

UPMC Enterprises is the innovation, commercialization, and venture capital arm of UPMC, a $26 billion healthcare provider and insurer based in Pittsburgh. With an emphasis on translational sciences and digital solutions, UPMC Enterprises provides its portfolio companies and partners with capital, connections, and resources to develop solutions to healthcare's most complex problems. Working in close collaboration with innovators from UPMC and the University of Pittsburgh Schools of the Health Sciences, as well as others worldwide, UPMC Enterprises strives to accelerate science from the bench to the bedside and has committed to investing $1 billion in novel drugs, diagnostics, and devices by 2024.

Media Contact
Kristen Mathis, ThriveAP, 1 1-952-540-7483, [email protected], https://www.thriveap.com/

LinkedIn

SOURCE ThriveAP


These press releases may also interest you

at 04:00
King Faisal Specialist Hospital and Research Centre (KFSHRC) has successfully performed 5,000 kidney transplants since the inception of its Transplant Program in 1981, placing it among a select group of leading global health centres that have...

at 04:00
IFPA (The International Federation of Psoriasis Associations) concluded its highly anticipated 7th IFPA Conference on World Psoriasis and Psoriatic Arthritis, held from June 27 to 29, 2024, in Stockholm, Sweden. Established in 2006, the conference...

at 03:43
IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented the clinical data and single-cell analysis of the fully human...

at 03:37
RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2024B, the latest version of the company's innovative treatment planning system. The new version comes with automation of important clinical workflows, such as automatic image...

at 03:15
TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer's disease (AD), has announced the submission of a UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM) for treatment of mild cognitive...

at 03:00
Kedrion Biopharma Inc. announced today that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo® in the U.S., following its...



News published on and distributed by: